The many faces of neuroendocrine differentiation in prostate cancer progression

Frontiers in Oncology

Volumn 4 MAR, Issue , 2014, Pages

  Terry, Stéphane ^a,b   Beltran, Himisha ^c  

^a INSERM U955   (France)

^b INSTITUT CURIE   (France)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Androgen receptor; Aurora kinase A; Cancer biology; Neuroendocrine differentiation; NRSF REST; Prostate cancer; Protocadherin; Small cell carcinoma

Indexed keywords

ADRENOMEDULLIN; ANDROGEN RECEPTOR; AURORA A KINASE; BOMBESIN; CALCITONIN; CD56 ANTIGEN; CHROMOGRANIN; FORSKOLIN; HEPATOCYTE NUCLEAR FACTOR 3BETA; INTERLEUKIN 6; MICRORNA; MICRORNA 106B; MICRORNA 25; MICRORNA 93; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM; SEROTONIN; SURVIVIN; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

BRACHYTHERAPY; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DISEASE COURSE; HIGH THROUGHPUT SCREENING; HUMAN; LUNG SMALL CELL CANCER; NEUROSECRETORY CELL; NONHUMAN; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME; TUMOR GROWTH; TUMOR MICROENVIRONMENT; WNT SIGNALING PATHWAY;

EID: 84901008773     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00060     Document Type: Review

References (111)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin (2013) 63:11-30. doi: 10.3322/caac.21166.
2. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene (2013) 32:5501-11. doi:10.1038/onc.2013.206.
3. Toren PJ, Gleave ME. Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. Asian J Androl (2013) 15:342-9. doi:10.1038/aja.2013.38.
4. Marker PC, Donjacour AA, Dahiya R, Cunha GR. Hormonal, cellular, and molecular control of prostatic development. Dev Biol (2003) 253:165-74. doi:10.1016/S0012-1606(02)00031-3.
5. Abrahamsson PA. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer (1999) 6:503-19. doi:10.1677/erc.0.0060503.
6. Bonkhoff H, Wernert N, Dhom G, Remberger K. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate (1991) 19:91-8. doi:10.1002/pros.2990190202.
7. Salido M, Vilches J, Lopez A. Neuropeptides bombesin and calcitonin induce resistance to etoposide induced apoptosis in prostate cancer cell lines. Histol Histopathol (2000) 15:729-38.
8. Xing N, Qian J, Bostwick D, Bergstralh E, Young CY. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate (2001) 48:7-15. doi:10.1002/pros.1076.
9. Daneshmand S, Dorff TB, Quek ML, Cai J, Pike MC, Nichols PW, et al. Ethnic differences in neuroendocrine cell expression in normal human prostatic tissue. Urology (2005) 65:1008-12. doi:10.1016/j.urology.2004.11.052.
10. Humphrey PA. Histological variants of prostatic carcinoma and their significance. Histopathology (2012) 60:59-74. doi:10.1111/j.1365-2559.2011.04039.x.
11. Evans AJ, Humphrey PA, Belani J, Van Der Kwast TH, Srigley JR. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol (2006) 30:684-93. doi:10.1097/00000478-200606000-00003.
12. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas (2010) 39:707-12. doi:10.1097/MPA.0b013e3181ec124e.
13. Wu C, Wyatt AW, Lapuk AV, McPherson A, McConeghy BJ, Bell RH, et al. Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. J Pathol (2012) 227:53-61. doi:10.1002/path.3987.
14. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J (2001) 18:1059-68. doi:10.1183/09031936.01.00275301.
15. Nicholson SA, Beasley MB, Brambilla E, Hasleton PS, Colby TV, Sheppard MN, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol (2002) 26:1184-97. doi:10.1097/00000478-200209000-00009.
16. Hansel DE, Nakayama M, Luo J, Abukhdeir AM, Park BH, Bieberich CJ, et al. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate (2009) 69:603-9. doi:10.1002/pros.20910.
17. Wong YN, Jack RH, Mak V, Henrik M, Davies EA. The epidemiology and survival of extrapulmonary small cell carcinoma in South East England, 1970-2004. BMC Cancer (2009) 9:209. doi:10.1186/1471-2407-9-209.
18. Deorah S, Rao MB, Raman R, Gaitonde K, Donovan JF. Survival of patients with small cell carcinoma of the prostate during 1973-2003: a population-based study. BJU Int (2012) 109:824-30. doi:10.1111/j.1464-410X.2011.10523.x.
19. Yao JL, Madeb R, Bourne P, Lei J, Yang X, Tickoo S, et al. Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol (2006) 30:705-12. doi:10.1097/00000478-200606000-00005.
20. Hu Y, Ippolito JE, Garabedian EM, Humphrey PA, Gordon JI. Molecular characterization of a metastatic neuroendocrine cell cancer arising in the prostates of transgenic mice. J Biol Chem (2002) 277:44462-74. doi:10.1074/jbc.M205784200.
21. Nakada SY, Di Sant'agnese PA, Moynes RA, Hiipakka RA, Liao S, Cockett AT, et al. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue. Cancer Res (1993) 53:1967-70.
22. Sauer CG, Roemer A, Grobholz R. Genetic analysis of neuroendocrine tumor cells in prostatic carcinoma. Prostate (2006) 66:227-34. doi:10.1002/pros.20338.
23. Chevalier S, Defoy I, Lacoste J, Hamel L, Guy L, Begin LR, et al. Vascular endothelial growth factor and signaling in the prostate: more than angiogenesis. Mol Cell Endocrinol (2002) 189:169-79. doi:10.1016/S0303-7207(01)00728-6.
24. Grobholz R, Griebe M, Sauer CG, Michel MS, Trojan L, Bleyl U. Influence of neuroendocrine tumor cells on proliferation in prostatic carcinoma. Hum Pathol (2005) 36:562-70. doi:10.1016/j.humpath.2005.02.019.
25. Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P, et al. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol (1996) 178:437-41. doi:10.1002/(SICI)1096-9896(199604)178:4<437::AID-PATH484>3.0.CO;2-4.
26. Cussenot O, Villette JM, Valeri A, Cariou G, Desgrandchamps F, Cortesse A, et al. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol (1996) 155:1340-3. doi:10.1097/00005392-199604000-00058.
27. Krauss DJ, Hayek S, Amin M, Ye H, Kestin LL, Zadora S, et al. Prognostic significance of neuroendocrine differentiation in patients with Gleason score 8-10 prostate cancer treated with primary radiotherapy. Int J Radiat Oncol Biol Phys (2011) 81:e119-25. doi:10.1016/j.ijrobp.2010.12.064.
28. Krauss DJ, Amin M, Stone B, Ye H, Hayek S, Cotant M, et al. Chromogranin a staining as a prognostic variable in newly diagnosed Gleason score 7-10 prostate cancer treated with definitive radiotherapy. Prostate (2014) 74:520-7. doi:10.1002/pros.22771.
29. Bang YJ, Pirnia F, Fang WG, Kang WK, Sartor O, Whitesell L, et al. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci U S A (1994) 91:5330-4. doi:10.1073/pnas.91.12.5330.
30. Shen R, Dorai T, Szaboles M, Katz AE, Olsson CA, Buttyan R. Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium. Urol Oncol (1997) 3:67-75. doi:10.1016/S1078-1439(97)00039-2.
31. Cindolo L, Cantile M, Vacherot F, Terry S, de la Taille A. Neuroendocrine differentiation in prostate cancer: from lab to bedside. Urol Int (2007) 79:287-96. doi:10.1159/000109711.
32. Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer (2007) 14:531-47. doi:10.1677/ERC-07-0061.
33. Deng X, Liu H, Huang J, Cheng L, Keller ET, Parsons SJ, et al. Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Res (2008) 68:9663-70. doi:10.1158/0008-5472.CAN-08-2229.
34. Frigo DE, McDonnell DP. Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation. Mol Cancer Ther (2008) 7:659-69. doi:10.1158/1535-7163.MCT-07-0480.
35. Ploussard G, Terry S, Maille P, Allory Y, Sirab N, Kheuang L, et al. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res (2010) 70:9253-64. doi:10.1158/0008-5472.CAN-10-1447.
36. Terry S, Maille P, Baaddi H, Kheuang L, Soyeux P, Nicolaiew N, et al. Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer. Neoplasia (2013) 15:761-72.
37. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, et al. LNCaP model of human prostatic carcinoma. Cancer Res (1983) 43:1809-18.
38. Wright ME, Tsai MJ, Aebersold R. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol (2003) 17:1726-37. doi:10.1210/me.2003-0031.
39. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol (2004) 45:586-92. doi:10.1016/j.eururo.2003.11.032.
40. Sasaki T, Komiya A, Suzuki H, Shimbo M, Ueda T, Akakura K, et al. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients. Eur Urol (2005) 48:224-9. doi:10.1016/j.eururo.2005.03.017.
41. Wafa LA, Palmer J, Fazli L, Hurtado-Coll A, Bell RH, Nelson CC, et al. Comprehensive expression analysis of L-DOPA decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. Hum Pathol (2007) 38:161-70. doi:10.1016/j.humpath.2006.07.003.
42. Berges RR, Vukanovic J, Epstein JI, Carmichel M, Cisek L, Johnson DE, et al. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res (1995) 1:473-80.
43. Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB, et al. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res (2004) 64:5489-95. doi:10.1158/0008-5472.CAN-03-3117.
44. Uchida K, Masumori N, Takahashi A, Itoh N, Kato K, Matusik RJ, et al. Murine androgen-independent neuroendocrine carcinoma promotes metastasis of human prostate cancer cell line LNCaP. Prostate (2006) 66:536-45. doi:10.1002/pros.20369.
45. Terry S, Ploussard G, Allory Y, Nicolaiew N, Boissiere-Michot F, Maille P, et al. Increased expression of class III beta-tubulin in castration-resistant human prostate cancer. Br J Cancer (2009) 101:951-6. doi:10.1038/sj.bjc.6605245.
46. Nordin A, Wang W, Welen K, Damber JE. Midkine is associated with neuroendocrine differentiation in castration-resistant prostate cancer. Prostate (2013) 73:657-67. doi:10.1002/pros.22607.
47. Nieto MA. Epithelial plasticity: a common theme in embryonic and cancer cells. Science (2013) 342:1234850. doi:10.1126/science.1234850.
48. Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI, Mosquera JM, et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol (2012) 30:e386-9. doi:10.1200/JCO.2011.41.5166.
49. Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, Perner S, Tomlins S, et al. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia (2007) 9:200-6. doi:10.1593/neo.07103.
50. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 1:487-95. doi:10.1158/2159-8290.CD-11-0130.
51. Lotan TL, Gupta NS, Wang W, Toubaji A, Haffner MC, Chaux A, et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol (2011) 24:820-8. doi:10.1038/modpathol.2011.7.
52. Lin C, Yang L, Tanasa B, Hutt K, Ju BG, Ohgi K, et al. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell (2009) 139:1069-83. doi:10.1016/j.cell.2009.11.030.
53. Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK, Varambally S, et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science (2009) 326:1230. doi:10.1126/science.1178124.
54. Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol (2002) 20:3072-80. doi:10.1200/JCO.2002.12.065.
55. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res (2013) 19:3621-30. doi:10.1158/1078-0432.CCR-12-3791.
56. Rosenthal SA, Sandler HM. Treatment strategies for high-risk locally advanced prostate cancer. Nat Rev Urol (2010) 7:31-8. doi:10.1038/nrurol.2009.237.
57. Bhattasali O, Chen LN, Tong M, Lei S, Collins BT, Krishnan P, et al. Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naive prostate cancer. Front Oncol (2013) 3:293. doi:10.3389/fonc.2013.00293.
58. Komiya A, Yasuda K, Nozaki T, Fujiuchi Y, Hayashi SI, Fuse H. Small cell carcinoma of the prostate after high-dose-rate brachytherapy for low-risk prostatic adenocarcinoma. Oncol Lett (2013) 5:53-6. doi:10.3892/ol.2012.998.
59. Otto T, Horn S, Brockmann M, Eilers U, Schuttrumpf L, Popov N, et al. Stabilization of N-Myc is a critical function of aurora A in human neuroblastoma. Cancer Cell (2009) 15:67-78. doi:10.1016/j.ccr.2008.12.005.
60. Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia (2013) 15:1-10.
61. Zhou Z, Flesken-Nikitin A, Corney DC, Wang W, Goodrich DW, Roy-Burman P, et al. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res (2006) 66:7889-98. doi:10.1158/0008-5472.CAN-06-0486.
62. Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, et al. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res (2012) 18:666-77. doi:10.1158/1078-0432.CCR-11-1867.
63. Tan HL, Sood A, Rahimi HA, Wang W, Gupta N, Hicks J, et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res (2014) 20:890-903. doi:10.1158/1078-0432.CCR-13-1982.
64. Wang J, Kim J, Roh M, Franco OE, Hayward SW, Wills ML, et al. Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene (2010) 29:2477-87. doi:10.1038/onc.2010.10.
65. Qi J, Nakayama K, Cardiff RD, Borowsky AD, Kaul K, Williams R, et al. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell (2010) 18:23-38. doi:10.1016/j.ccr.2010.05.024.
66. Danza G, Di Serio C, Rosati F, Lonetto G, Sturli N, Kacer D, et al. Notch signaling modulates hypoxia-induced neuroendocrine differentiation of human prostate cancer cells. Mol Cancer Res (2012) 10:230-8. doi:10.1158/1541-7786.MCR-11-0296.
67. Mirosevich J, Gao N, Gupta A, Shappell SB, Jove R, Matusik RJ. Expression and role of Foxa proteins in prostate cancer. Prostate (2006) 66:1013-28. doi:10.1002/pros.20299.
68. Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmbhatt S, et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol (2012) 227:286-97. doi:10.1002/path.4047.
69. Liang H, Studach L, Hullinger RL, Xie J, Andrisani OM. Down-regulation of RE-1 silencing transcription factor (REST) in advanced prostate cancer by hypoxia-induced miR-106b 25. Exp Cell Res (2014) 320:188-99. doi:10.1016/j.yexcr.2013.09.020.
70. Schoenherr CJ, Anderson DJ. The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes. Science (1995) 267:1360-3. doi:10.1126/science.7871435.
71. Ooi L, Wood IC. Chromatin crosstalk in development and disease: lessons from REST. Nat Rev Genet (2007) 8:544-54. doi:10.1038/nrg2100.
72. Svensson C, Ceder J, Iglesias-Gato D, Chuan YC, Pang ST, Bjartell A, et al. REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer. Nucleic Acids Res (2014) 42(2):999-1015. doi:10.1093/nar/gkt921.
73. Morishita H, Yagi T. Protocadherin family: diversity, structure, and function. Curr Opin Cell Biol (2007) 19:584-92. doi:10.1016/j.ceb.2007.09.006.
74. van Roy F. Beyond E-cadherin: roles of other cadherin superfamily members in cancer. Nat Rev Cancer (2014) 14:121-34. doi:10.1038/nrc3647.
75. Terry S, Queires L, Gil-Diez-De-Medina S, Chen MW, de la Taille A, Allory Y, et al. Protocadherin-PC promotes androgen-independent prostate cancer cell growth. Prostate (2006) 66:1100-13. doi:10.1002/pros.20446.
76. Yang X, Chen MW, Terry S, Vacherot F, Chopin DK, Bemis DL, et al. A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells. Cancer Res (2005) 65:5263-71. doi:10.1158/0008-5472.CAN-05-0162.
77. Blanco P, Sargent CA, Boucher CA, Mitchell M, Affara NA. Conservation of PCDHX in mammals; expression of human X/Y genes predominantly in brain. Mamm Genome (2000) 11:906-14. doi:10.1007/s003350010177.
78. Chen MW, Vacherot F, de la Taille A, Gil-Diez-De-Medina S, Shen R, Friedman RA, et al. The emergence of protocadherin-PC expression during the acquisition of apoptosis-resistance by prostate cancer cells. Oncogene (2002) 21:7861-71. doi:10.1038/sj.onc.1205991.
79. Bachtrog D. Y-chromosome evolution: emerging insights into processes of Y-chromosome degeneration. Nat Rev Genet (2013) 14:113-24. doi:10.1038/nrg3366.
80. Priddle TH, Crow TJ. The protocadherin 11X/Y (PCDH11X/Y) gene pair as determinant of cerebral asymmetry in modern Homo sapiens. Ann N Y Acad Sci (2013) 1288:36-47. doi:10.1111/nyas.12042.
81. Otto SJ, McCorkle SR, Hover J, Conaco C, Han JJ, Impey S, et al. A new binding motif for the transcriptional repressor REST uncovers large gene networks devoted to neuronal functions. J Neurosci (2007) 27:6729-39. doi:10.1523/JNEUROSCI.0091-07.2007.
82. Tan YP, Li S, Jiang XJ, Loh W, Foo YK, Loh CB, et al. Regulation of protocadherin gene expression by multiple neuron-restrictive silencer elements scattered in the gene cluster. Nucleic Acids Res (2010) 38:4985-97. doi:10.1093/nar/gkq246.
83. Uysal-Onganer P, Kawano Y, Caro M, Walker MM, Diez S, Darrington RS, et al. Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells. Mol Cancer (2010) 9:55. doi:10.1186/1476-4598-9-55.
84. Yu X, Wang Y, Degraff DJ, Wills ML, Matusik RJ. Wnt/beta-catenin activation promotes prostate tumor progression in a mouse model. Oncogene (2011) 30:1868-79. doi:10.1038/onc.2010.560.
85. Bisson I, Prowse DM. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res (2009) 19:683-97. doi:10.1038/cr.2009.43.
86. de la Taille A, Rubin MA, Chen MW, Vacherot F, De Medina SG, Burchardt M, et al. Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin Cancer Res (2003) 9:1801-7.
87. Bruxvoort KJ, Charbonneau HM, Giambernardi TA, Goolsby JC, Qian CN, Zylstra CR, et al. Inactivation of Apc in the mouse prostate causes prostate carcinoma. Cancer Res (2007) 67:2490-6. doi:10.1158/0008-5472.CAN-06-3028.
88. Arnold SJ, Robertson EJ. Making a commitment: cell lineage allocation and axis patterning in the early mouse embryo. Nat Rev Mol Cell Biol (2009) 10:91-103. doi:10.1038/nrm2618.
89. Mulligan KA, Cheyette BN. Wnt signaling in vertebrate neural development and function. J Neuroimmune Pharmacol (2012) 7:774-87. doi:10.1007/s11481-012-9404-x.
90. Huang Z, Bao S. Ubiquitination and deubiquitination of REST and its roles in cancers. FEBS Lett (2012) 586:1602-5. doi:10.1016/j.febslet.2012.04.052.
91. Lawinger P, Venugopal R, Guo ZS, Immaneni A, Sengupta D, Lu W, et al. The neuronal repressor REST/NRSF is an essential regulator in medulloblastoma cells. Nat Med (2000) 6:826-31. doi:10.1038/77565.
92. Fuller GN, Su X, Price RE, Cohen ZR, Lang FF, Sawaya R, et al. Many human medulloblastoma tumors overexpress repressor element-1 silencing transcription (REST)/neuron-restrictive silencer factor, which can be functionally countered by REST-VP16. Mol Cancer Ther (2005) 4:343-9. doi:10.1158/1535-7163.MCT-04-0228.
93. Coulson JM, Edgson JL, Woll PJ, Quinn JP. A splice variant of the neuron-restrictive silencer factor repressor is expressed in small cell lung cancer: a potential role in derepression of neuroendocrine genes and a useful clinical marker. Cancer Res (2000) 60:1840-4.
94. Su X, Gopalakrishnan V, Stearns D, Aldape K, Lang FF, Fuller G, et al. Abnormal expression of REST/NRSF and Myc in neural stem/progenitor cells causes cerebellar tumors by blocking neuronal differentiation. Mol Cell Biol (2006) 26:1666-78. doi:10.1128/MCB.26.5.1666-1678.2006.
95. Terry S, Yang X, Chen MW, Vacherot F, Buttyan R. Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer. J Cell Biochem (2006) 99:402-10. doi:10.1002/jcb.20983.
96. Azoulay S, Terry S, Chimingqi M, Sirab N, Faucon H, Gil-Diez-De-Medina S, et al. Comparative expression of Hedgehog ligands at different stages of prostate carcinoma progression. J Pathol (2008) 216:460-70. doi:10.1002/path.2427.
97. Chen M, Tanner M, Levine AC, Levina E, Ohouo P, Buttyan R. Androgenic regulation of hedgehog signaling pathway components in prostate cancer cells. Cell Cycle (2009) 8:149-57. doi:10.4161/cc.8.1.7532.
98. Chen M, Feuerstein MA, Levina E, Baghel PS, Carkner RD, Tanner MJ, et al. Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells. Mol Cancer (2010) 9:89. doi:10.1186/1476-4598-9-89.
99. Nishihara S, Tsuda L, Ogura T. The canonical Wnt pathway directly regulates NRSF/REST expression in chick spinal cord. Biochem Biophys Res Commun (2003) 311:55-63. doi:10.1016/j.bbrc.2003.09.158.
100. Gates KP, Mentzer L, Karlstrom RO, Sirotkin HI. The transcriptional repressor REST/NRSF modulates hedgehog signaling. Dev Biol (2010) 340:293-305. doi:10.1016/j.ydbio.2010.01.029.
101. Meirmanov S, Nakashima M, Rogounovitch T, Fukuda E, Nakayama T, Sato F, et al. Small cell carcinoma of the endometrium: report of a case with analysis of Wnt/beta-catenin pathway. Pathol Res Pract (2003) 199:551-8. doi:10.1078/0344-0338-00461.
102. Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, Baylin SB. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature (2003) 422:313-7. doi:10.1038/nature01493.
103. Park KS, Martelotto LG, Peifer M, Sos ML, Karnezis AN, Mahjoub MR, et al. A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat Med (2011) 17:1504-8. doi:10.1038/nm.2473.
104. Vokes SA, Ji H, McCuine S, Tenzen T, Giles S, Zhong S, et al. Genomic characterization of Gli-activator targets in sonic hedgehog-mediated neural patterning. Development (2007) 134:1977-89. doi:10.1242/dev.001966.
105. Yu X, Wang Y, Jiang M, Bierie B, Roy-Burman P, Shen MM, et al. Activation of beta-catenin in mouse prostate causes HGPIN and continuous prostate growth after castration. Prostate (2009) 69:249-62. doi:10.1002/pros.20877.
106. Petraki C, Vaslamatzis M, Petraki K, Revelos K, Alevizopoulos N, Papanastasiou P, et al. Prostate cancer with small-cell morphology: an immunophenotypic subdivision. Scand J Urol Nephrol (2005) 39:455-63. doi:10.1080/00365590500199855.
107. Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol (2013) 63:920-6. doi:10.1016/j.eururo.2012.08.053.
108. Burchardt M, Burchardt T, Shabsigh A, Ghafar M, Chen MW, Anastasiadis A, et al. Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells. Prostate (2001) 48:225-30. doi:10.1002/pros.1101.
109. Bernard D, Pourtier-Manzanedo A, Gil J, Beach DH. Myc confers androgen-independent prostate cancer cell growth. J Clin Invest (2003) 112:1724-31. doi:10.1172/JCI200319035.
110. Shen MM, Abate-Shen C. Pten inactivation and the emergence of androgen-independent prostate cancer. Cancer Res (2007) 67:6535-8. doi:10.1158/0008-5472.CAN-07-1271.
111. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 19:575-86. doi:10.1016/j.ccr.2011.04.008.